 |
Appointments:
Walter L. Palmer Distinguished Service
Professor
Department of Medicine and Human
Genetics
Section of Hematology/Oncology
Director, Hematology/Oncology Fellowship
Program
Director, Center for Clinical Cancer
Genetics and Global Health
Cancer Research Center
Associate Dean for Global Health
Committee on Cancer Biology
Committee on Genetics
Committee of Clinical & Translational Science
|
Education:
M.D./B.S. Medicine Univeristy of Ibadan,
1980
|
Contact:
Phone: (773) 702-1632
Fax: (773)
834-3834
E-Mail: folopade@bsd.uchicago.edu
Address:
The University of Chicago
KCBD 8100
900 East 57th Street
Chicago, Illinois 60637
Webpage (Medical Center)
Webpage (Global Health)
|
Related Research Interests:
Cancer
Cytogenetics
|
|
Olufunmilayo Olopade, M.D.
Molecular Genetics of Breast Cancer, Tumor Suppressor
Genes, Mechanisms of Oncogene Amplification
Research Summary
Dr. Olopade's laboratory has sought to identify and
characterize genes relevant to tumor progression, determine their role
in inherited susceptibility, and perform genetic epidemiologic analyses
translatable to clinical practice. The laboratory is also focused on
understanding epigenetic mechanisms underlying abnormal gene expression
including aberrant CpG-island-promoter methylation of specific tumor
suppressor genes, global changes in genomic DNA methylation, and
alterations in histone modification (deacetylation and methylation).
Our primary tumor model is breast cancer.
Selected Papers
Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA,
Foulkes WD, Warner E, Olopade O, Weber EAB, McLennan
J, Sun P. The risk of ovarian cancer after breast cancer in BRCA1
and BRCA 2 carriers. Gynecol Oncol. 96:222-226, 2005.
Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Isgur
Bergsagel K, Huiart L, Olopade OI, Sobol H, Sanger W,
Hogg D, Weisenburger D. Phenotypic heterogeneity in multiple
myeloma families. J Clin Oncol. 23:685-93, 2005.
Fackenthal JD, Sveen L, Gao Q, Kohlmeir EK, Adebamowo C, Ogundiran TO,
Adenipekun AA, Oyesegun R, Campbell O, Rotimi C, Akang EE, Das S, Olopade
OI. Complete allelic analysis of BRCA1 and BRCA2
variants in young Nigerian breast cancer patients complete allelic
analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer
patients. J Med Genet. 42:276-81, 2005.
Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch
hT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade
O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K,
Sun P, Narod SA. A comparison of bilateral breast cancers in BRCA
carriers. Cancer Epidemiol Biomarkers Prev. 14:1534-8, 2005.
Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs
C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S,
Pasini B, Ainsworth P, Gershoni-Baruch R, Foulkes WD, Klijn J, Tung N,
Rennert G, Olopade O, Couch F, Wagner T, Olsson H,
Sun P, Weitzel JN, Narod SA. Effect of pregnancy as a risk factor
for breast cancer in BRCA1/BRCA2 mutation carriers. Int J
Cancer. 117:988-91, 2005.
Li H, Giger ML, Olopade OI, Margolis A, Lan L,
Chinander MR. Computerized texture analysis of mamographic
parenchymal patterns of digitized mammograms. Acad Radiol.
12:863-73, 2005.
Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs
C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P,
Friedman E, Daly M, Garber JE, Karlan B, Olopade OI,
Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P,
Narod SA. Age at menarche and the risk of breast cancer in BRCA1
and BRCA2 mutation carriers. Cancer Causes Control. 16:667-74,
2005.
Riddenstrale KK, Grushko ta, Kim H-J, Olopade OI. Single day FISH
procedure for paraffin-embedded tissue sections using a mircrowave
oven. Bio Tecniques 39:316-320, 2005.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs
C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R,
Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S,
Armstrong K, Weber BL; PROSE Study Group. Effect of short-term
hormone replacement therapy on breast cancer risk reduction after
bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation
carriers: the PROSE Study Group. J Clin Oncol. 23:7804-10,
2005.
Nanda R, Schumm, LP, Cummings S, Ademuyiwa F, Cobleigh M, Esserman L,
Lindor NM, Neuhausen SL, and Olopade OI, Genetic
Testing in an Ethnically Diverse Cohort of High-Risk Women: A
comparative Analysis of BRCA1 and BRCA2 Mutations in American Families
of European and African Ancestry. JAMA 294:1925-33, 2005.
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J,
Fackenthal J, Tretiakova M, Das S, Olopade OI, BRCA1
Promoter Methylation in Sporadic Breast Cancer is Associated with
Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy. Cancer
Research 65:10692-9, 2005.
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing
C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O,
Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod
SA, TamoxifEn and contralateral breast cancer in BRCA1 and BRCA2
carriers: An update. Int J Cancer. 118:2281-84, 2005.
Medved M, Newstead GM, Abe H, Zamora MA, Olopade OI,
Karczmar GS.High spectral and spatial resolution MRI of breast lesions:
preliminary clinical experience. AJR Am J Roentgenol. 186:30-7, 2006.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI,
Moore DT, Perou CM. Phenotypic evaluation of the basal-like
subtype of invasive breast carcinoma. Mod Pathol 19:264-71, 2006.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA,
Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Saywer LR, Wu J,
Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP,
Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF,
Ellis MJ, Olopade OI, Bernard PS Perou CM. The
molecular portraits of breast tumors are conserved across microarray
platforms. BMC Genomics. 2006 Apr 27;7:96.
Chen Y, Borowicz S, Fackenthal J, Collart FR, Myatt E, Moy S, Babnigg
G, Wilton R, Boernke WE, Schiffer M, Stevens FJ, Olopade OI.
Primary structure-based function characterization of BRCT domain
replicates in BRCA1. Biochem Biophys Res Commun. 2006 Jun
23;345(1):188-96. Epub 2006 Apr 21.
Olopade OI, Schwartsmann G, Saijo N,
Thomas CR Jr. Disparities in cancer care: a worldwide perspective and
roadmap for change. J Clin Oncol. 2006 May 10;24(14):2135-6.
Hong AL, Huo D, Kim HJ, Niu Q, Frankenthal DL, Cummings SA, John EM,
West DW, Whittemore AS, Das S, Olopade OI.
UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin
levels in an ethnically diverse cohort of women. Drug Metab Dispos.
2007; 35(8):1254-61]
Herschkowitz JI, Simin K, Weigman VJ, et al.. Identification of
conserved gene expression features between murine mammary carcinoma
models and human breast tumors. Genome Biol. 2007 May 10;8(5):R76 [Epub
ahead of print].
Couch FJ, Sinilnikova O, Vierkant RA, et al. Consortium of
Investigators of Modifiers of BRCA1/2. AURKA F31I polymorphism and
breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium
of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol
Biomarkers Prev;16:1416-21, 2007.
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer
DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade
OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA,
Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants
in multiethnic cohorts. Int J Cancer;121:2661-7, 2007.
Huo D, Kim HJ, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O,
Adenipekun A, Niu Q, Sveen L, Fackenthal JD, Fackenthal DL, Das S, Cox
N, Rienzo AD, Olopade OI. Genetic polymorphisms in
uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in
Africans. Breast Cancer Res Treat. 2007 Oct 2.
Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade
OI. Estrogen receptor alpha, BRCA1, and FANCF promoter
methylation occur in distinct subsets of sporadic breast cancers.
Breast Cancer Res Treat. Oct 12 2007.
Gao B, Xie XJ, Huang C, Shames DS, Chen TT, Lewis CM, Bian A, Zhang B,
Olopade OI, Garber JE, Euhus DM, Tomlinson GE, Minna JD.
RASSF1A polymorphism A133S is associated with early onset breast cancer
in BRCA1/2 mutation carriers. Cancer Res. 68:22-5, 2008.
Garner CP, Ding YC, John EM, Ingles SA, Olopade OI,
Huo D, Adebamowo C, Ogundiran T, Neuhausen SL. Genetic variation in
IGFBP2 and IGFBP5 is associated with breast cancer in populations of
African descent. Hum Genet. 2008 Apr;123(3):247-55.
Huo D, Adebamowo CA, Ogundiran TO, Akang EF, Campbell O, Adenipekun A,
Cummings S, Fackenthal J, Ademuyiwa F, Cook, M Ahsan H, Olopade
OI. Parity and breastfeeding are protective against breast
cancer in Nigerian women. Br J Cancer. 2008 Mar 11;98(5):992-6.
Olopade OI, Grushko TA, Nanda R, Huo D.
Advances in breast cancer: pathways to personalized medicine. Clin
Cancer Res. 2008 Dec 15;14(24):7988-99.
Chen Y, Olopade OI. MYC in breast tumor progression.
Expert Rev Anticancer Ther. 2008 Oct;8(10):1689-98.
Zhang B, Fackenthal JD, Niu Q, Huo D, Sveen WE, DeMarco T, Adebamowo
CA, Ogundiran T, Olopade OI. Evidence for an ancient
BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam
Cancer. 2009;8(1):15-22.
|
Faculty and Research
Programs
|